Your browser doesn't support javascript.
loading
Quality of life in pre- and postmenopausal patients with early breast cancer: a comprehensive analysis from the prospective MaLife project.
Marschner, Norbert; Trarbach, Tanja; Rauh, Jacqueline; Meyer, Dirk; Müller-Hagen, Sigrun; Harde, Johanna; Dille, Stephanie; Kruggel, Lisa; Jänicke, Martina.
Afiliación
  • Marschner N; Praxis für interdisziplinäre Onkologie und Hämatologie, Wirthstrasse 11c, 79110, Freiburg, Germany. manuskript@onkologie-freiburg.de.
  • Trarbach T; MVZ des Klinikums Wilhelmshaven, Zentrum für Tumorbiologie, Wilhelmshaven, Germany.
  • Rauh J; GIM Gemeinschaftspraxis Innere Medizin, Witten, Germany.
  • Meyer D; OSP Göttingen, Göttingen, Germany.
  • Müller-Hagen S; Hämatologisch-Onkologischer Schwerpunkt Schnelsen, Hamburg, Germany.
  • Harde J; Department of Biostatistics, iOMEDICO, Freiburg, Germany.
  • Dille S; Medical Department, iOMEDICO, Freiburg, Germany.
  • Kruggel L; Clinical Epidemiology and Health Economics, iOMEDICO, Freiburg, Germany.
  • Jänicke M; Clinical Epidemiology and Health Economics, iOMEDICO, Freiburg, Germany.
Breast Cancer Res Treat ; 175(3): 701-712, 2019 Jun.
Article en En | MEDLINE | ID: mdl-30868393
PURPOSE: Quality of life (QoL) plays an important role in recovery-especially after an incisive diagnosis such as breast cancer. Here, we present a comprehensive assessment of QoL for pre- and postmenopausal patients, starting from initial systemic treatment of early breast cancer until 3 years later, in patients from a so-called "real-world" setting. METHODS: 251 premenopausal and 478 postmenopausal patients with early breast cancer have been recruited into the longitudinal MaLife project within the prospective, multicentre, German Tumour Registry Breast Cancer between 2011 and 2015. The questionnaires FACT-G, FACT-Taxane, FACT-ES, EORTC QLQ-BR23, BFI and HADS were filled in at start of treatment (T0), 6, 12, 24 and 36 months later. The proportion of patients with clinically meaningful changes at 36 months was determined. RESULTS: This first interim analysis shows that the FACT-G global QoL improved over time regardless of the menopausal status. However, clinically meaningful decrease of social/family well-being (48-51%), arm symptoms (44-49%) and symptoms of neurotoxicity (55-56%) was frequently reported 3 years after start of treatment. Many premenopausal patients also reported a clinically meaningful worsening of endocrine symptoms (64%), emotional well-being (36%) and fatigue intensity (37%). Additionally, 3 years after start of treatment, 15% of the patients were classified as doubtful cases and 18% as definite cases of anxiety. CONCLUSIONS: Despite improvements in global QoL, breast cancer survivors report worsened ailments 3 years after start of therapy. Follow-up care should distinguish between premenopausal patients needing special attention for emotional/menopausal issues, and postmenopausal patients needing particular care regarding physical concerns.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Calidad de Vida / Neoplasias de la Mama / Premenopausia / Posmenopausia Tipo de estudio: Clinical_trials / Observational_studies / Qualitative_research Aspecto: Patient_preference Límite: Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Revista: Breast Cancer Res Treat Año: 2019 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Países Bajos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Calidad de Vida / Neoplasias de la Mama / Premenopausia / Posmenopausia Tipo de estudio: Clinical_trials / Observational_studies / Qualitative_research Aspecto: Patient_preference Límite: Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Revista: Breast Cancer Res Treat Año: 2019 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Países Bajos